Impairment of endothelium-dependent pulmonary vasodilation in patients with primary pulmonary hypertension

Brett, S. J.; Simon, J.; Gibbs, R.; Pepper, J. R.; Evans, T. W.
January 1996
Thorax;Jan1996, Vol. 51 Issue 1, p89
Academic Journal
No abstract available.


Related Articles

  • Vasodilators and Prostaglandin Inhibitors in Primary Pulmonary Hypertensions. Hermiller, James B.; Bambach, Dennis; Thompson, Michael J.; Huss, Patricia; Fontana, Mary E.; Magorien, Raymond D.; Unverferth, Donald V.; Leier, Carl V. // Annals of Internal Medicine;Oct82, Vol. 97 Issue 4, p480 

    Deals with a study which determined and compared the resting hemodynamic effects of various vasodilator agents and prostaglandin inhibitors in patients with primary pulmonary hypertension. Background on primary pulmonary hypertension; Patient population; Baseline hemodynamic data; Discussion...

  • Right Ventricular Unloading: Lessons from the Left. Pranciosa, Joseph A.; Fischer, Herbert A. // Annals of Internal Medicine;Nov81, Vol. 95 Issue 5, p647 

    Editorial. Comments on the adverse hemodynamic effects of phentolamine in primary pulmonary hypertension. Effect of vasodilators on pulmonary vascular resistance; Mechanism of action of vasodilators.

  • Paradoxical Effect of Prostacyclin Infusion in a Patient with Primary Pulmonary Hypertension. Younger, Jared R.; Lui, Charles Y. // Angiology;May/Jun2004, Vol. 55 Issue 3, p341 

    Prostacyclin treatment successfully delays the need for lung transplantation in many patients with progressive primary pulmonary hypertension by vasodilating pulmonary arteries. However, the treatment of pulmonary hypertension with prostacyclin may cause a paradoxical increase in pulmonary...

  • Treatment of Primary Pulmonary Hypertension with Nifedipine. Rubin, Lewis J.; Nicod, Pascal; Hillis, L. David; Firth, Brian G. // Annals of Internal Medicine;Oct83, Vol. 99 Issue 4, p433 

    Evaluates the potential value of nifedipine treatment for primary pulmonary hypertension, hemodynamic and scintigraphic measurements. Information on primary pulmonary hypertension; Potent systemic vasodilator agents that have been reported to reduce pulmonary vascular resistance in some...

  • Pulmonary Hypertension from Chronic Pulmonary Thromboembolism. Rich, Stuart; Levitzky, Sidney; Brundage, Bruce H. // Annals of Internal Medicine;Mar88, Vol. 108 Issue 3, p425 

    Provides information on pulmonary hypertension from chronic pulmonary thromboembolism. Reason for the development of pulmonary hypertension; Thrombosis in pulmonary hypertension from chronic pulmonary thromboembolism; Assays of plasma fibrinolytic components in patients with primary pulmonary...

  • Nitric oxide and other novel therapies for pulmonary hypertension. Napoli, Claudio; Loscalzo, Joseph // Journal of Cardiovascular Pharmacology & Therapeutics;Mar2004, Vol. 9 Issue 1, p1 

    Pulmonary hypertension is an uncommon, yet devastating, syndrome with a complex underlying pathobiology. Hypoxia, inflammation, and increased shear stress appear to be the primary pathogenic events; however, mechanisms by which these processes lead to pulmonary hypertension remain incompletely...

  • Immediate and Long-term Hemodynamic and Clinical Effects of Sildenefil in Patients With Pulmonary Arterial Hypertension Receiving Vasodilator Therapy. Bhatia, Sundeep; Frantz, Robert P.; Severson, Cathy J.; Durst, Louise A.; McGoon, Michael D. // Mayo Clinic Proceedings;Oct2003, Vol. 78 Issue 10, p1207 

    Determines the immediate and long-term effects of adding sildenefil, a phosphodiesterase-5 inhibitor to the medical regimen of patients with pulmonary arterial hypertension (PAH). Pulmonary vasodilator effect in patients already receiving vasodilators for PAH.

  • Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension. Fukumoto, Y.; Matoba, T.; Ito, A.; Tanaka, H.; Kishi, T.; Hayashidani, S.; Abe, K.; Takeshita, A.; Shimokawa, H. // Heart;Mar2005, Vol. 91 Issue 3, p391 

    Presents a letter to the editor related to acute vasodilator effects of fusadil in patients with severe pulmonary hypertension.

  • Recognition and Management of Pulmonary Hypertension. Wanstall, J.C.; Jeffery, T.K. // Drugs;Dec1998, Vol. 56 Issue 6, p989 

    Pulmonary hypertension (mean pulmonary arterial pressure >20mm Hg at rest or >30mm Hg during exercise) occurs (i) as primary pulmonary hypertension (no known underlying cause), (ii) as persistent pulmonary hypertension of the newborn or (iii) secondary to a variety of lung and cardiovascular...

  • Vasodilator Therapy for Primary Pulmonary Hypertension. Packer, Milton // Annals of Internal Medicine;Aug85, Vol. 103 Issue 2, p258 

    Evaluates the efficacy of vasodilator therapy for primary pulmonary hypertension. Information on how vasolidator drugs are administered; Medical cases; Discussion on the results of the treatment.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics